このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

ICARuS 術後腹腔内化学療法 (EPIC) および温熱腹腔内化学療法 (HIPEC) (ICARuS)

2026年10月1日 更新者:Memorial Sloan Kettering Cancer Center

ICARuS (細胞減少手術後の腹腔内化学療法): 虫垂、結腸または結腸の新生物に対する最適な細胞減少手術 (CRS) 後の早期術後腹腔内化学療法 (EPIC) および温熱腹腔内化学療法 (HIPEC) の多施設ランダム化第 II 相試験孤立性腹膜転移を伴う直腸

This is the first randomized trial comparing Early post-operative intraperitoneal chemotherapy (EPIC) and hyperthermic intraperitoneal chemotherapy (HIPEC) for appendiceal and colorectal cancer. The purpose of this study is to find out what effects, good and/or bad, EPIC and HIPEC after cytoreductive surgery have on the patient and the appendiceal, rectal or colon cancer.

調査の概要

研究の種類

介入

入学 (実際)

292

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Florida
      • Miami、Florida、アメリカ
        • University of Miami
    • Missouri
      • St Louis、Missouri、アメリカ、63110
        • Washington University School of Medicine
    • New Jersey
      • Basking Ridge、New Jersey、アメリカ、07920
        • Memorial Sloan Kettering Basking Ridge (Consent and Follow up)
      • Middletown、New Jersey、アメリカ、07748
        • Memorial Sloan Kettering Monmouth (Consent and Follow up)
      • Montvale、New Jersey、アメリカ、07645
        • Memorial Sloan Kettering Bergen (Consent and Follow up)
    • New York
      • Commack、New York、アメリカ、11725
        • Memorial Sloan Kettering Commack (Consent and Follow up)
      • Harrison、New York、アメリカ、10604
        • Memorial Sloan Kettering Westchester (Consent and Follow up)
      • New York、New York、アメリカ、10065
        • Memorial Sloan Kettering Cancer Center
      • Uniondale、New York、アメリカ、11553
        • Memorial Sloan Kettering Nassau (Consent and Follow up)

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Patient's age 18 years or older, both genders.
  • Clinical diagnosis of appendiceal or colorectal neoplasm with peritoneal mucinosis or metastasis.
  • Patient must be planning to undergo complete cytoreduction of all peritoneal disease.
  • ECOG performance status ≤ 1.
  • Hematology: ANC ≥ 1,500/ μL; Platelets > 75,000/ μL.
  • Adequate Renal function Creatinine <1.5 x the upper limit of normal (ULN) or calculated creatinine clearance of ≥ 50ml/min.
  • Adequate Hepatic function: Bilirubin less than 1.5mg/dL; (except in patients with Gilbert's Syndrome, who must have a total bilirubin less than 3.0mg/dL).
  • Women with childbearing potential who are negative for pregnancy test (urine or blood) and who agree to use effective contraceptive method. Reliable contraception should be used from trial screening and must be continued throughout the study. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant.
  • A man participating in this study must agree to utilize reliable barrier form of contraception for the duration of the study.
  • Signed and dated written informed consent to participate in this clinical trial must be obtained prior to any study procedure.
  • Subjects with a history of endometrial cancer are eligible only if they presented with a stage lower than 1A and if the histology was a subtype other than poorly differentiated.

Exclusion Criteria:

  • Subjects who have previously undergone intraperitoneal chemotherapy.
  • Subjects with classical carcinoid
  • Tumors of low malignant potential
  • Other prior malignancies, except for cured non-melanoma skin cancer, curatively treated in situ carcinoma of the cervix, adequately treated malignancies for which there has been no evidence of activity for more than 3 years or indolent tumors for which observation over three years is a reasonable option.
  • Presence of clinically apparent or suspected metastasis to sites other than lymph nodes or peritoneal surfaces.
  • Women who are pregnant or lactating.
  • Subjects with a condition which may interfere with the subjects' ability to understand the requirements of the study.
  • Active coronary artery disease (defined as unstable angina or a positive cardiac stress test).
  • Subjects with a history of coronary artery disease may be included if they have had a normal stress test within 60 days of enrollment and/or were cleared by MSK cardiology.
  • Uncontrolled hypertension defined as >140/90 and not cleared for surgery at the time of consent.
  • New York Heart Association (NYHA) Class II or higher Congestive heart failure.
  • Restrictive or obstructive pulmonary disease that would limit study compliance or place the patient at unacceptable risk for participation in the study.
  • History of cerebrovascular disease. that would limit study compliance or place the patient at unacceptable risk for participation in the study.
  • Subjects with other concurrent severe medical problems unrelated to the malignancy that would significantly limit full compliance with the study or places them at an unacceptable risk for participation in the study.
  • Patients with known floxuridine, leucovorin ,or mitomycin allergy.
  • Evidence of extensive intraperitoneal adhesions at the time of surgery which prohibits intraperitoneal therapy, as determined by the operating surgeon.
  • Any condition that would preclude the ability to deliver appropriate IP therapy.
  • Use of an oral medication, lacking a suitable non-oral substitute, that if held for up to ten days, would be felt an unacceptable risk by the investigator.
  • Life expectancy < 12 weeks.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Appendiceal, no chemotherapy within 6 months prior to surgery

First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.

  1. Exposure to chemotherapy in the prior 6 months vs. no such exposure
  2. Appendix vs. Colon or Rectum Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm.

Optimal Surgical Debulking

実験的:Appendiceal, chemotherapy within 6 months prior to surgery

First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.

  1. Exposure to chemotherapy in the prior 6 months vs. no such exposure
  2. Appendix vs. Colon or Rectum • Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm.

Optimal Surgical Debulking

実験的:Colorectal, no chemotherapy within 6 months prior to surgery

First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.

  1. Exposure to chemotherapy in the prior 6 months vs. no such exposure
  2. Appendix vs. Colon or Rectum • Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm.

Optimal Surgical Debulking

実験的:Colorectal, chemotherapy within 6 months prior to surgery

First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.

  1. Exposure to chemotherapy in the prior 6 months vs. no such exposure
  2. Appendix vs. Colon or Rectum • Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm.

Optimal Surgical Debulking

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
disease-free survival
時間枠:3 years

Documentation of tumor recurrence will be made based on surveillance CT/PET CT scans at time points as determined by attending radiologist, with clinical correlation from the treating physician.

3 years

二次結果の測定

結果測定
メジャーの説明
時間枠
surgical toxicity grade 3 to 5
時間枠:up to 60 days

We will evaluate toxicity up to 30 days postoperatively for any surgical Grade 3-5 complications/toxicites or chemotherapy related Grade 4 or 5 toxicities. Surgical morbidity will be graded using the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0

up to 60 days
chemotherapy toxicity grade 3 to 5
時間枠:up to 60 days

We will evaluate toxicity up to 30 days postoperatively for any surgical Grade 3-5 complications/toxicities or chemotherapy related Grade 4 or 5 toxicities.

up to 60 days

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Garrett Nash, MD, MPH、Memorial Sloan Kettering Cancer Center

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始

2013年3月1日

一次修了 (推定)

2027年9月1日

研究の完了 (推定)

2027年9月1日

試験登録日

最初に提出

2013年3月13日

QC基準を満たした最初の提出物

2013年3月18日

最初の投稿 (推定)

2013年3月21日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月2日

QC基準を満たした最後の更新が送信されました

2026年10月1日

最終確認日

2026年10月1日

詳しくは

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する